Zevra Therapeutics
Targeting improved therapies for pain, ADHD and other CNS indications.
Launch date
Employees
Market cap
€363m
Enterprise valuation
€372m (Public information from Sep 2024)
Share price
$8.02 ZVRA
Kissimmee Florida (HQ), Coralville Iowa (founding location)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 13.3m | 28.7m | 10.5m | 25.7m | 26.0m | 91.1m | 163m |
| % growth | 3 % | 116 % | (63 %) | 146 % | 1 % | 250 % | 79 % |
| EBITDA | (4.7m) | 8.0m | (24.1m) | (64.5m) | (50.4m) | (16.3m) | 50.4m |
| % EBITDA margin | (35 %) | 28 % | (230 %) | (251 %) | (194 %) | (18 %) | 31 % |
| Profit | (12.8m) | (8.6m) | (41.5m) | (43.6m) | (69.7m) | (21.9m) | 32.3m |
| % profit margin | (96 %) | (30 %) | (397 %) | (170 %) | (268 %) | (24 %) | 20 % |
| EV / revenue | 3.6x | 10.7x | 5.3x | 7.9x | 15.7x | 4.6x | 2.4x |
| EV / EBITDA | -10.3x | 38.6x | -2.3x | -3.2x | -8.1x | -25.8x | 7.6x |
| R&D budget | 8.8m | 10.2m | 19.6m | - | - | - | - |
| R&D % of revenue | 67 % | 35 % | 188 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$650k | Series A | ||
$3.5m | Series B | ||
| N/A | $6.9m | Early VC | |
| N/A | $762k | Debt | |
$60.0m | Debt | ||
| N/A | $4.0m | Early VC | |
* | N/A | $56.0m Valuation: $56.0m | IPO |
* | $100m | Post IPO Debt | |
* | N/A | $60.0m | Post IPO Equity |
| Total Funding | €13.7m | ||
Recent News about Zevra Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Zevra Therapeutics
Edit
ACQUISITION by Zevra Therapeutics May 2022
ACQUISITION by Zevra Therapeutics Aug 2023